Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method for enhancing 4-valent epidemic meningococcal polysaccharide protein bonder immunogenicity

A technology of epidemic meningitis and polysaccharide protein, which is applied in the direction of carrier-binding antigen/hapten components, antibacterial drugs, and pharmaceutical formulations, and can solve problems such as weak immunogenicity

Active Publication Date: 2014-10-15
KANVAX BIOPHARM
View PDF3 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The clinical application of the 4-valent meningococcal polysaccharide conjugate vaccine has achieved results, however, some groups are still weakly immunogenic and need to be updated with the development of more immunogenic products

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for enhancing 4-valent epidemic meningococcal polysaccharide protein bonder immunogenicity
  • Method for enhancing 4-valent epidemic meningococcal polysaccharide protein bonder immunogenicity
  • Method for enhancing 4-valent epidemic meningococcal polysaccharide protein bonder immunogenicity

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0032] The specific implementation method of the present invention is illustrated below, but not limited to the following examples.

[0033] The implementation method of the present invention is to use the method of gene recombination to express and purify the CRM197A protein carrier and the CRM197A protein carrier with the universal epitope peptide P30 in the expression system of Escherichia coli engineering bacteria; then, the four groups of epidemic meninges Inflammatory coccus capsular polysaccharide (referred to as Men) was covalently linked to the P30CRM197A protein carrier to prepare the Men-P30CRM197A conjugate; after mixing four monovalent polysaccharide-protein conjugates to prepare a vaccine, mice were immunized, and blood was collected to obtain immune serum; The polysaccharide-specific antibody titer in mouse serum was detected by ELISA to evaluate the immunogenicity of polysaccharide-protein conjugates.

[0034] Step 1: Preparation of protein carrier and meningoc...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a method for enhancing 4-valent epidemic meningococcal polysaccharide protein bonder immunogenicity, and the method is as follows: adding all-powerful epitope peptide (P30) into CRM197A (A chain of diphtheria toxin variant 197), using genetic recombinant Escherichia coli to produce a P30-containing protein carrier P30CRM197A of the A chain of the diphtheria toxin variant 197 (CRM197); and connecting 4 different serogroups (comprising A, C, W135 and Y) capsular polysaccharides to the P30-containing protein carrier P30CRM197A by covalent bonds to form a 4-valent epidemic meningococcal polysaccharide-P30CRM197A bonder; compared with a 4-valent epidemic meningococcal polysaccharide-CRM197A bonder obtained by a corresponding protein carrier CRM197A which does not contain the all-powerful epitope peptide (P30), the immunogenicity of the 4-valent epidemic meningococcal polysaccharide-P30CRM197A bonder obtained by the method is increased by 3-5 times than that of a contrast.

Description

technical field [0001] The invention relates to a method for enhancing the immunogenicity of a polysaccharide-protein conjugate of 4-valent epidemic meningococcus. Background technique [0002] When the polysaccharide is covalently linked to the protein carrier, the polysaccharide of the hapten can be converted into a whole antigen, so that the immunogenicity of the polysaccharide is enhanced. The polysaccharide-protein conjugated vaccine synthesized by this method has been widely used in children, successfully preventing bacterial infections including pneumococcus, meningococcus and Haemophilus influenzae type b. [0003] There are many protein carriers used to synthesize polysaccharide-protein conjugates, such as tetanus toxoid, diphtheria toxoid, diphtheria toxin variant CRM197, and Haemophilus epidemic surface protein D produced by genetic recombination technology; however, due to different The immunogenicity of the protein, the immunogenicity of polysaccharide-protein ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/385A61K47/48A61P31/04
Inventor 李建平
Owner KANVAX BIOPHARM
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com